Page 74 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy

14. Moher, D., et al., Preferred reporting items for systematic review and meta- analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 2015. 4(1).
15. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer, 2009. 45(2): p. 228-47.
16. Powles, T., et al., MPDL3280A (anti-PD-L1) treatment leads to clinical
activity in metastatic bladder cancer. Nature, 2014. 515(7528): p. 558-62.
17. Neil Howard, S., et al., Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Journal of Clinical Oncology, 2014.
32(15_suppl): p. 3002-3002.
18. Roy, S.H., et al., A study of MPDL3280A, an engineered PD-L1 antibody in
patients with locally advanced or metastatic tumors. Journal of Clinical
Oncology, 2013. 31(15_suppl): p. 3000-3000.
19. Kang, Y.K., et al., Nivolumab in patients with advanced gastric or gastro-
oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017.
20. Bang, Y.J., et al., Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res, 2017. 23(19): p. 5671-5678.
21. Postow, M.A., M.K. Callahan, and J.D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol, 2015. 33(17): p. 1974-82.
22. Brahmer, J.R., et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 2012. 366(26): p. 2455-65.
23. Li, M., Q. Pan, and M.P. Peppelenbosch, Should Nivolumab-Induced Colitis Be Treated by Infliximab? Clin Gastroenterol Hepatol, 2017. 15(10): p. 1637.
24. Patel, K., et al., Expression of programmed death-ligand 1 (PD-L1), mismatch repair status, and Epstein-Barr status in locally advanced gastric adenocarcinoma: Correlation to clinical outcome. J Clin Oncol, 2016. 34.
25. Chung, H.C., et al., Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. J Clin Oncol, 2016. 34(4).
Chapter 3
Chapter 3
68
72